NEW YORK, July 24 – Applera will spend $75 million over the next year to realize a return on its "substantial investment in sequencing the human genome,” by establishing a wide-ranging drug discovery and diagnostics development program across its three businesses, Celera Genomics, Celera Diagnostics, and Applied Biosystems, Applera CEO Tony White said Tuesday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.